Vaccinex, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Maurice Zauderer
- Full Time Employees
- 23
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1895 Mount Hope Avenue Rochester NY United States of America 14620
- IPO Date
- Aug 9, 2018
- CIK
- 0001205922
- Website
- vaccinex.com
- Similar Companies
- Business
- Vaccinex, Inc. (Nasdaq: VCNX) is a clinical-stage biotechnology company that discovers and develops targeted biotherapeutics to treat cancer, neurodegenerative diseases including Huntington's and Alzheimer's, and autoimmune disorders through inhibition of semaphorin 4D (SEMA4D); its lead product candidate is pepinemab (VX15/2503), a humanized monoclonal IgG4 antibody that blocks SEMA4D signaling to enhance immune cell infiltration in tumors and reduce neuroinflammation in chronic brain disorders; the company also offers the proprietary ActivMAb antibody discovery platform for generating antibodies against complex targets such as multipass membrane proteins like GPCRs and ion channels, enabling partnerships for oncology and other therapeutic areas. Founded in 1997 and headquartered in Rochester, New York, Vaccinex operates primarily in the United States with global commercial rights to pepinemab and focuses on clinical advancement through investigator-sponsored trials and collaborations targeting patient populations with unmet needs in oncology (non-small cell lung cancer, head and neck squamous cell carcinoma, pancreatic adenocarcinoma, melanoma) and neurology (early manifest Huntington's disease, mild cognitive impairment in Alzheimer's). Recent developments include multiple project deals for the ActivMAb platform announced in November 2024 with presentations on successful antibody discovery campaigns for cancer immunotherapy at the Society for Immunotherapy of Cancer (SITC) annual meeting; improved immunity data correlating with clinical benefit from pepinemab combination treatments reported at SITC in November 2024; warrant exercises generating $6.2 million in gross proceeds in September 2024; positive topline results from the phase 1b/2 SIGNAL-AD trial in early Alzheimer's disease in 2024 showing safety, tolerability, and trends of slowed cognitive decline in mild cognitive impairment patients; and ongoing collaborations such as with Merck on the KEYNOTE-B84 study in head and neck cancer, Merck KGaA on NSCLC, and partners including the Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Emory University, and University of Rochester.
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
Vaccinex Reports 2025 Annual Financial Results
Head to Head Contrast: Evofem Biosciences (NASDAQ:EVFM) versus Vaccinex (NASDAQ:VCNX)
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain
Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer's Disease
Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate Update
Vaccinex Reports 2023 Financial Results and Provides Corporate Update
Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology
Vaccinex, Inc. Announces Reverse Stock Split
Vaccinex Announces Pricing of $3.7 Million PIPE Financing
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule